The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...

Norms recognized for decades in Washington by both parties no longer appear to apply to the Trump White House, former ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...

NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli ...